Celltrion
As of the edition of 20 October 2026, Celltrion runs 10 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Withdrawn from market | 1 |
| Status not established | 8 |
| Total | 10 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Infliximab | Ended 2018 (orphan exclusivity) | 3 |
A route B row is one company at one target.
Where its trials are
- Infections: 3 trials led
- Lungs and airways: 3 trials led
- Hormones: 2 trials led